BACKGROUND AND PURPOSE: The impact of second surgery and overall predictors of outcome following GBM recurrence remains controversial, with few definitive studies published to date. This study sought to identify major predictors of survival after second surgery. METHODS: We collected clinical, pathological and radiographic data through a retrospective review of patient charts. All patients underwent elective surgery for GBM recurrence at our institution in the past 6 years. Kaplan Meier, with log-rank test and Breslow test, was applied to determine and compare significance of
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